Bio-Thera Solutions And Hikma Pharma Say FDA Approved STARJEMZA Injection

The FDA has approved STARJEMZA (ustekinumab-hmny) Injection, a biosimilar to Janssen's Stelara, developed by Bio-Thera Solutions and to be commercialized by Hikma Pharmaceuticals in the U.S. This marks Bio-Thera's third FDA-approved product and offers a potentially lower-cost alternative to Stelara, a human monoclonal antibody used to treat inflammatory and immune responses related to conditions like psoriasis, Crohn's disease, and ulcerative colitis.

Analysis

The U.S. Food and Drug Administration has granted approval for STARJEMZA (ustekinumab-hmny) Injection, a biosimilar referencing Janssen's Stelara, marking a significant regulatory achievement for Bio-Thera Solutions Ltd. and Hikma Pharmaceuticals PLC. This approval represents Bio-Thera's third product to receive FDA clearance, underscoring its capabilities in biosimilar development and manufacturing, for which it retains responsibility under an August 2021 licensing and commercialization agreement. Hikma Pharmaceuticals is tasked with the commercialization of STARJEMZA in the United States, positioning it to compete with Stelara, a human monoclonal antibody that inhibits IL-12 and IL-23 for treating inflammatory conditions such as psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The strongly positive sentiment indicated by a score of 0.8, coupled with a market impact score of 0.6, suggests a favorable market reception and highlights the potential for STARJEMZA to provide a more cost-effective treatment alternative, thereby accessing a substantial market segment within immunology.

Key Decisions for Investors

• Investors should consider this FDA approval a positive development for both Bio-Thera Solutions and Hikma Pharmaceuticals, potentially enhancing their revenue prospects and strengthening their positions in the competitive biosimilar market.
• The successful approval of a third product by Bio-Thera may warrant a re-evaluation of its pipeline strength and long-term growth trajectory, given its demonstrated development and manufacturing capabilities.
• For Hikma Pharmaceuticals, the focus shifts to effective U.S. commercialization of STARJEMZA; investors should monitor market launch details, uptake rates, and competitive dynamics against the originator product, Stelara, and other potential biosimilars.